New pill could help severe asthma sufferers breathe easier

NCT ID NCT07532265

Recruiting now Disease control Sponsor: Kinaset Therapeutics Inc Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jul 29, 2026 · Updated 3 times

Summary

This study tests a new drug called frevecitinib (KN-002) in 512 adults with severe asthma that is not well controlled by their current treatments. Participants will take one of three doses of the drug or a placebo daily for 12 weeks. The main goal is to see if the drug improves lung function and asthma control.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

asthma chronic asthma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

SEVERE ASTHMA

Contacts and locations

Locations

Research site
RECRUITING

Lancaster, California, 93534, United States
Research site
RECRUITING

San Jose, California, 95117, United States
Research site
NOT_YET_RECRUITING

Brandon, Florida, 33511, United States
Research site
RECRUITING

Miami, Florida, 33137, United States
Research site
RECRUITING

Tampa, Florida, 33607, United States
Research site
NOT_YET_RECRUITING

Chicago, Illinois, 60612, United States
Research site
NOT_YET_RECRUITING

Kansas City, Missouri, 66160, United States
Research site
RECRUITING

Charlotte, North Carolina, 28277, United States
Research site
NOT_YET_RECRUITING

Pittsburgh, Pennsylvania, 15213, United States
Research site
RECRUITING

Rock Hill, South Carolina, 29732, United States
Research site
RECRUITING

Dallas, Texas, 75225, United States
Research site
RECRUITING

Houston, Texas, 77099, United States
Research site
RECRUITING

San Antonio, Texas, 78258, United States
Research site
NOT_YET_RECRUITING

Williamsburg, Virginia, 23188, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.